Compagnie Lombard Odier SCmA’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.49M | Sell |
13,065
-16
| -0.1% | -$7.09K | 0.07% | 115 |
|
|
2026
Q1 | $5.84M | Buy |
13,081
+416
| +3% | +$194K | 0.07% | 102 |
|
|
2025
Q4 | $5.74M | Buy |
12,665
+100
| +0.8% | +$43.1K | 0.06% | 99 |
|
|
2025
Q3 | $4.92M | Hold |
12,565
| – | – | 0.05% | 104 |
|
|
2025
Q2 | $5.59M | Hold |
12,565
| – | – | 0.07% | 96 |
|
|
2025
Q1 | $6.09M | Buy |
12,565
+3,000
| +31% | +$1.4M | 0.07% | 102 |
|
|
2024
Q4 | $3.85M | Sell |
9,565
-864
| -8% | -$400K | 0.06% | 103 |
|
|
2024
Q3 | $4.85M | Buy |
10,429
+3,200
| +44% | +$1.54M | 0.08% | 97 |
|
|
2024
Q2 | $3.39M | Buy |
7,229
+2,929
| +68% | +$1.27M | 0.06% | 107 |
|
|
2024
Q1 | $1.8M | Buy |
4,300
+3,000
| +231% | +$1.27M | 0.03% | 137 |
|
|
2023
Q4 | $529K | Hold |
1,300
| – | – | 0.01% | 216 |
|
|
2023
Q3 | $452K | Sell |
1,300
-600
| -32% | -$210K | 0.01% | 194 |
|
|
2023
Q2 | $669K | Hold |
1,900
| – | – | 0.02% | 158 |
|
|
2023
Q1 | $599K | Sell |
1,900
-3,614
| -66% | -$1.08M | 0.02% | 186 |
|
|
2022
Q4 | $1.59M | Buy |
5,514
+4,214
| +324% | +$1.28M | 0.04% | 139 |
|
|
2022
Q3 | $376K | Sell |
1,300
-330
| -20% | -$94.9K | 0.01% | 237 |
|
|
2022
Q2 | $460K | Hold |
1,630
| – | – | 0.01% | 209 |
|
|
2022
Q1 | $425K | Hold |
1,630
| – | – | 0.01% | 231 |
|
|
2021
Q4 | $358K | Buy |
1,630
+1,250
| +329% | +$243K | 0.01% | 283 |
|
|
2021
Q3 | $69K | Hold |
380
| – | – | ﹤0.01% | 468 |
|
|
2021
Q2 | $76K | Buy |
380
+130
| +52% | +$27.2K | ﹤0.01% | 442 |
|
|
2021
Q1 | $54K | Buy |
+250
| New | +$54.9K | ﹤0.01% | 501 |
|
|
2020
Q3 | – | Sell |
-325
| Closed | -$94K | – | 577 |
|
|
2020
Q2 | $94K | Buy |
325
+75
| +30% | +$20.3K | ﹤0.01% | 330 |
|
|
2020
Q1 | $59K | Buy |
+250
| New | +$57.3K | ﹤0.01% | 343 |
|
|
2019
Q1 | – | Sell |
-300
| Closed | -$50K | – | 608 |
|
|
2018
Q4 | $50K | Sell |
300
-200
| -40% | -$34.7K | ﹤0.01% | 390 |
|
|
2018
Q3 | $96K | Hold |
500
| – | – | ﹤0.01% | 356 |
|
|
2018
Q2 | $85K | Buy |
+500
| New | +$77.5K | ﹤0.01% | 378 |
|
|
2015
Q2 | – | Sell |
-537
| Closed | -$63K | – | 939 |
|
|
2015
Q1 | $63K | Buy |
+537
| New | +$64.3K | ﹤0.01% | 760 |
|
|
2014
Q4 | – | Sell |
-1,818
| Closed | -$204K | – | 863 |
|
|
2014
Q3 | $204K | Sell |
1,818
-4,371
| -71% | -$416K | 0.01% | 501 |
|
|
2014
Q2 | $586K | Buy |
6,189
+2,506
| +68% | +$176K | 0.02% | 288 |
|
|
2014
Q1 | $261K | Buy |
3,683
+1,357
| +58% | +$107K | 0.01% | 452 |
|
|
2013
Q4 | $173K | Buy |
+2,326
| New | +$162K | 0.01% | 559 |
|
Other funds holding VRTX
Compagnie Lombard Odier SCmA's VRTX Position: Q2 2026 in Review
Compagnie Lombard Odier SCmA reduced its Vertex Pharmaceuticals (VRTX) stake by 0.12% in Q2 2026, selling an estimated $7.09K and leaving 13,065 shares worth $6.49M. The position accounts for 0.07% of the portfolio, ranked #115.
Compagnie Lombard Odier SCmA first reported a position in VRTX in Q4 2013 and has held it in 32 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Compagnie Lombard Odier SCmA held 13,065 shares of Vertex Pharmaceuticals worth $6.49M as of Q2 2026.
- Compagnie Lombard Odier SCmA sold 16 Vertex Pharmaceuticals shares in Q2 2026, an estimated $7.09K.
- Vertex Pharmaceuticals made up 0.07% of Compagnie Lombard Odier SCmA's portfolio in Q2 2026, its #115 holding.
- Compagnie Lombard Odier SCmA first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 32 quarters since.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2026, filed 29 Jul 2026.